Kidney Failure, Chronic
Conditions
Keywords
Indoxyl sulfate, AST-120
Brief summary
Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been shown to retard the deterioration of renal function in CKD patients through reducing the levels of IS. IS was reported to promote aortic calcification and stimulate the proliferation of vascular smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With this background, the investigators will performed the study whether AST-120 improve the endothelial dysfunction in CKD patients.
Detailed description
The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients
Interventions
DRUGKremezin
AST-120 2g three times a day
Sponsors
Ewha Womans University
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with Chronic kidney disease (Stage3 - Stage4) * Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information
Exclusion criteria
* Acute gastric or duodenal ulcer * Severe constipation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of FMD(Flow Mediated Dilatation) | 6 months | FMD (Flow Mediated Dilatation): percent change of FMD response to hyperemia and after sublingual nitroglycerin on brachial artery. |
Secondary
| Measure | Time frame |
|---|---|
| Level of Indoxyl Sulfate | 3 months, 6 months |
Countries
South Korea
Contacts
Primary ContactMINA YU, MD
Backup ContactGil-Soon Yang, NR
Outcome results
None listed